Close
Novotech
Jabsco PureFlo 21 Single Use

Pneumococcal Vaccines Aided By New Approach By Singapore

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Smarter Trial Design Improves Drug Development Speed

Optimization of clinical trial protocols through innovative designs and strategic endpoint selection directly accelerates drug development speed and improves operational reliability.

Data Driven Decisions Improve Drug Development Outcomes

Integrating comprehensive analytics and real-world data into clinical planning allows pharmaceutical companies to optimize trial design and significantly improve patient outcomes.

Efficient Early Strategies Enable Faster Clinical Progress

Implementing optimized early-stage frameworks and enhancing trial readiness allows pharmaceutical sponsors to accelerate clinical timelines and maintain high R&D efficiency.
- Advertisement -

Numerous disease-causing bacteria like Streptococcus pneumoniae, happen to be encased in a sugar layer that is known as the capsular polysaccharide (CPS). This layer is often essential when it comes to infections.

In a discovery that can indeed be termed as ground-breaking by the scientists from the Yong Ling Lin School of Medicine of the National University of Singapore, the traits of the CPS that aid the bacteria so as to colonise the human respiratory track were pinpointed.
The study also showed that structures of the CPS capsule as well as its types of linkages and combinations, greatly matter in letting the bacteria attach better and survive on the lining of the upper and lower human respiratory tracts as well.

This inference can go on to shed more light on the CPS type range that will be a part of future vaccines since the current vaccines against S. pneumoniae do not cover the numerous types of CPS that are produced by the bacteria.

S. pneumoniae happens to be a major driver when it comes to septicaemia, pneumonia, as well as meningitis. To thwart the deadly infections, the pneumococcal vaccines are administered so as to stimulate the production of antibodies against the CPS.

That said, the bacteria can go on to manipulate their structure so as to evade the antibodies. This biochemical warfare results in more than a hundred kinds of CPSs that are produced by S. pneumoniae, which elevates the challenge when it comes to producing effective vaccines.

Latest stories

Related stories

Smarter Trial Design Improves Drug Development Speed

Optimization of clinical trial protocols through innovative designs and strategic endpoint selection directly accelerates drug development speed and improves operational reliability.

Data Driven Decisions Improve Drug Development Outcomes

Integrating comprehensive analytics and real-world data into clinical planning allows pharmaceutical companies to optimize trial design and significantly improve patient outcomes.

Efficient Early Strategies Enable Faster Clinical Progress

Implementing optimized early-stage frameworks and enhancing trial readiness allows pharmaceutical sponsors to accelerate clinical timelines and maintain high R&D efficiency.

Early Insights Reduce Risk in Drug Development Programs

Leveraging early-stage data and translational research allows pharmaceutical companies to mitigate drug development risk and implement adaptive strategies for higher success.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »